Boston closes $600 million public offering:
This article was originally published in Clinica
Boston Scientific has completed a public debt offering worth $600m in senior notes. The Natick, Massachusetts company had originally planned to offer $500m but increased this amount to $600m, due, reportedly, to high demand for the 10-year notes. Boston says it plans to use the proceeds to repay commercial paper borrowings and for other general corporate purposes.
You may also be interested in...
House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”